en
Scientific article
English

Pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency : a cohort study

Published inDevelopmental medicine & child neurology, vol. 64, no. 6, p. 789-798
Publication date2022-06
First online date2022-01-26
Abstract

Aim: To investigate the short-term efficacy and safety of high-dose pyridoxine and pyridoxal 5-phosphate (P5P) in the treatment of inherited glycosylphosphatidylinositol (GPI) deficiency-associated epilepsy.

Method: Participants with genetically confirmed GPI deficiency were treated with oral pyridoxine or P5P as compassionate use in an agreed-upon clinical regimen. Pyridoxine (20-30 mg/kg/day) was used for 3 months. Baseline evaluation included 4 weeks of prospective seizure data and one video electroencephalogram (EEG). Seizure frequency was captured daily. The EEG was repeated after reaching maximum dosage of pyridoxine. Pyridoxine was switched to P5P (20-30 mg/kg/day) if seizure burden was unchanged after 3 months' treatment. Another EEG was done after 3 months of P5P treatment. Primary outcome measures were reduction of seizure frequency and EEG improvements.

Results: Seven participants (one female, six males; age range 5-23 year; mean age 11 years 10 months, SD 5 year 2 months) were included. The genetic causes of inherited GPI deficiency were phosphatidylinositol N-acetylglucosaminyltransferase subunit A/T/V deficiency. All had drug-resistant epilepsy and neurodevelopmental impairment. We observed more than 50% seizure frequency reduction in 2 out of 7 and less than 50% reduction in another 3 out of 7 participants. No participants reached seizure freedom. No remarkable changes in electrophysiological findings were observed in 6 out of 7 participants treated with pyridoxine or P5P when comparing the baseline and follow-up EEGs.

Interpretation: We observed no long-lasting electrophysiological improvements during treatment but pyridoxine may reduce seizure frequency or burden in inherited GPI deficiency.

What this paper adds: Inherited glycosylphosphatidylinositol (GPI) deficiency often causes early-onset and drug-resistant epilepsy. Vitamin B6is a potential disease-specific treatment; however, efficacy and safety are ill-defined. Pyridoxine may reduce seizure frequency or burden in inherited GPI deficiency. Pyridoxine and P5P could prove to be a useful treatment in some individuals with inherited GPI deficiency and epilepsy.

eng
Keywords
  • Cohort Studies
  • Drug Resistant Epilepsy / drug therapy
  • Epilepsy / complications
  • Epilepsy / drug therapy
  • Epilepsy / genetics
  • Female
  • Glycosylphosphatidylinositols / deficiency
  • Glycosylphosphatidylinositols / therapeutic use
  • Humans
  • Infant
  • Male
  • Phosphates / therapeutic use
  • Prospective Studies
  • Pyridoxal Phosphate / therapeutic use
  • Pyridoxine / therapeutic use
  • Seizures / drug therapy
  • Seizures / etiology
Citation (ISO format)
BAYAT, Allan et al. Pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency : a cohort study. In: Developmental medicine & child neurology, 2022, vol. 64, n° 6, p. 789–798. doi: 10.1111/dmcn.15142
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0012-1622
17views
0downloads

Technical informations

Creation03/05/2024 2:36:50 PM
First validation05/07/2024 3:11:46 PM
Update time05/07/2024 3:11:46 PM
Status update05/07/2024 3:11:46 PM
Last indexation05/07/2024 3:11:50 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack